{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:39:37Z","timestamp":1788316777002,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40744-024-00660-7","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:01:36Z","timestamp":1713459696000},"page":"691-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial"],"prefix":"10.1007","volume":"11","author":[{"given":"Kurt","family":"de Vlam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J.","family":"McVeigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"8","key":"660_CR1","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/acr.21994","volume":"65","author":"V Strand","year":"2013","unstructured":"Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial spondyloarthritis in United States rheumatology practices: assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken). 2013;65(8):1299\u2013306.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10089","key":"660_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"4","key":"660_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002281-200007000-00002","volume":"12","author":"E Feldtkeller","year":"2000","unstructured":"Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol. 2000;12(4):239\u201347.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"660_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11136-010-9771-9","volume":"20","author":"H Bodur","year":"2011","unstructured":"Bodur H, Ataman S, Rezvani A, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res. 2011;20(4):543\u20139.","journal-title":"Qual Life Res"},{"key":"660_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.006","volume":"52","author":"SC Kieskamp","year":"2022","unstructured":"Kieskamp SC, Paap D, Carbo MJG, et al. Central sensitization has major impact on quality of life in patients with axial spondyloarthritis. Semin Arthritis Rheum. 2022;52:151933.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"660_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3899\/jrheum.160411","volume":"45","author":"LE Dean","year":"2018","unstructured":"Dean LE, Macfarlane GJ, Jones GT. Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the Scotland Registry for Ankylosing Spondylitis. J Rheumatol. 2018;45(1):62\u20139.","journal-title":"J Rheumatol"},{"issue":"6","key":"660_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"660_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000430","volume":"3","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Hermann KG, et al. Effect of certolizumab pegol over 96\u00a0weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017;3(1):e000430.","journal-title":"RMD Open"},{"issue":"9","key":"660_CR9","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","volume":"161","author":"SN Raja","year":"2020","unstructured":"Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976\u201382.","journal-title":"Pain"},{"issue":"1","key":"660_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00393-019-0654-3","volume":"79","author":"TW Kim","year":"2020","unstructured":"Kim TW, Son SM, Lee JS. Neuropathic pain in ankylosing spondylitis: a meta-analysis. Z Rheumatol. 2020;79(1):95\u2013102.","journal-title":"Z Rheumatol"},{"issue":"6","key":"660_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/art.37920","volume":"65","author":"Q Wu","year":"2013","unstructured":"Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study. Arthritis Rheum. 2013;65(6):1494\u2013503.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"660_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1590\/S0482-50042010000600005","volume":"50","author":"VF Azevedo","year":"2010","unstructured":"Azevedo VF, EoS P, Felippe LR, Moreira RA. Occurrence of fibromyalgia in patients with ankylosing spondylitis. Rev Bras Reumatol. 2010;50(6):646\u201350.","journal-title":"Rev Bras Reumatol"},{"issue":"9","key":"660_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00296-007-0344-3","volume":"27","author":"V Aloush","year":"2007","unstructured":"Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int. 2007;27(9):865\u20138.","journal-title":"Rheumatol Int"},{"issue":"6","key":"660_CR14","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647\u201356.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"660_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomized, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"660_CR16","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16\u00a0week results of a phase\u00a03 randomized, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"9993","key":"660_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase\u00a03 randomized trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"10217","key":"660_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomized, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"10086","key":"660_CR19","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomized, double-blind, placebo-controlled period of the SPIRIT-P2 phase\u00a03 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"2","key":"660_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, et al. Efficacy and safety of ixekizumab through 52\u00a0weeks in two phase\u00a03, randomized, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"660_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/art.21337","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(4):502\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"660_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3758\/BRM.40.3.879","volume":"40","author":"KJ Preacher","year":"2008","unstructured":"Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879\u201391.","journal-title":"Behav Res Methods"},{"issue":"1","key":"660_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41927-021-00205-3","volume":"5","author":"AA Deodhar","year":"2021","unstructured":"Deodhar AA, Mease PJ, Rahman P, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial spondyloarthritis: COAST-V\/W 52-week results. BMC Rheumatol. 2021;5(1):35.","journal-title":"BMC Rheumatol"},{"issue":"5","key":"660_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s13075-014-0470-8","volume":"16","author":"HG Schaible","year":"2014","unstructured":"Schaible HG. Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther. 2014;16(5):470.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"660_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2011.01.079","volume":"493","author":"N Noma","year":"2011","unstructured":"Noma N, Khan J, Chen IF, et al. Interleukin-17 levels in rat models of nerve damage and neuropathic pain. Neurosci Lett. 2011;493(3):86\u201391.","journal-title":"Neurosci Lett"},{"issue":"8","key":"660_CR26","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.celrep.2019.10.085","volume":"29","author":"H Luo","year":"2019","unstructured":"Luo H, Liu HZ, Zhang WW, et al. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 2019;29(8):2384\u201397.e5.","journal-title":"Cell Rep"},{"issue":"1","key":"660_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1152\/physrev.00040.2019","volume":"101","author":"R Kuner","year":"2021","unstructured":"Kuner R, Kuner T. Cellular circuits in the brain and their modulation in acute and chronic pain. Physiol Rev. 2021;101(1):213\u201358.","journal-title":"Physiol Rev"},{"issue":"15","key":"660_CR28","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1056\/NEJMoa1204471","volume":"368","author":"TD Wager","year":"2013","unstructured":"Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. N Engl J Med. 2013;368(15):1388\u201397.","journal-title":"N Engl J Med"},{"issue":"3","key":"660_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuron.2015.06.005","volume":"87","author":"MN Baliki","year":"2015","unstructured":"Baliki MN, Apkarian AV. Nociception, pain, negative moods, and behavior selection. Neuron. 2015;87(3):474\u201391.","journal-title":"Neuron"},{"issue":"1","key":"660_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/mmr.2016.6018","volume":"15","author":"C Sun","year":"2017","unstructured":"Sun C, Zhang J, Chen L, et al. IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines. Mol Med Rep. 2017;15(1):89\u201396.","journal-title":"Mol Med Rep"},{"issue":"5","key":"660_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00401-015-1402-7","volume":"129","author":"A Waisman","year":"2015","unstructured":"Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol. 2015;129(5):625\u201337.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"660_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","volume":"13","author":"H Kebir","year":"2007","unstructured":"Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173\u20135.","journal-title":"Nat Med"},{"key":"660_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999407","volume":"13","author":"X Jiang","year":"2022","unstructured":"Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022;13:999407.","journal-title":"Front Immunol"},{"key":"660_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-2094-7-27","volume":"7","author":"L Leung","year":"2010","unstructured":"Leung L, Cahill CM. TNF-alpha and neuropathic pain\u2013a review. J Neuroinflammation. 2010;7:27.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"660_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.gene.2013.05.069","volume":"527","author":"AS Lee","year":"2013","unstructured":"Lee AS, Ellman MB, Yan D, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527(2):440\u20137.","journal-title":"Gene"},{"issue":"4","key":"660_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000097202","volume":"2","author":"WA Banks","year":"1995","unstructured":"Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 1995;2(4):241\u20138.","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"660_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/brainsci6010006","volume":"6","author":"G Mukandala","year":"2016","unstructured":"Mukandala G, Tynan R, Lanigan S, O\u2019Connor JJ. The effects of hypoxia and inflammation on synaptic signaling in the CNS. Brain Sci. 2016;6(1):6.","journal-title":"Brain Sci"}],"updated-by":[{"DOI":"10.1007\/s40744-024-00686-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00660-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:20:26Z","timestamp":1718432426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00660-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00660-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40744-024-00686-x","asserted-by":"object"}]},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40744-024-00686-x","URL":"https:\/\/doi.org\/10.1007\/s40744-024-00686-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kurt de Vlam has received grant\/research support from Celgene and Galapagos; consultancy fees from Celgene, Eli Lilly, Galapagos, Novartis, and UCB; and speaker fees from Celgene, Eli Lilly, Galapagos, Novartis, and UCB. Walter P. Maksymowych is Chief Medical Officer of CARE Arthritis Limited, has acted as a paid consultant\/participated in advisory boards for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB; received research and\/or educational grants from AbbVie, Novartis, Pfizer, and UCB; and received speaker fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. Proton Rahman has received consulting fees from Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, and Pfizer, and has also received research grants from Janssen and Novartis. Philip Mease declares research grants, consultation fees, and\/or speaker honoraria from AbbVie, Amgen, Bristol Myers, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB. Philip G. Conagah reports speakers\u2019 bureaus for AbbVie, Eli Lilly, Novartis, and consultancies with AbbVie, Eli Lilly, Genascense, GSK, Galapagos, Grunenthal, Janssen, Levicept, Merck, Moebius, Novartis, Stryker, Takeda, and TrialSpark. Gaia Gallo, Venkatesh Krishnan, Conor J. McVeigh, Jeffrey Lisse, Danting Zhu, and Rebecca J. Bolce are all employees and shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"COAST-V was carried out in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All investigation sites received approval from the appropriate authorized institutional review board or ethics committee. All patients provided written consent before the study-related procedures were carried out. The master ethics committee was Schulman Associates IRB, Cincinnati, OH, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}